Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation

20 Jan 2022

Abstract excerpt

Cellular energy metabolism is reprogrammed in cancer to fuel proliferation. In oncological therapy, treatment resistance remains an obstacle and is frequently linked to metabolic perturbations. Identifying metabolic changes as vulnerabilities opens up novel approaches for the prevention or targeting of acquired therapy resistance. Insights into metabolic alterations underlying ruthenium-based chemotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Epigenetics and DNA Methylation
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35213972
DOI: 10.3390/pharmaceutics14020238

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose DeprivationPMID 35213972Read ↗

mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerabilitySemantic proximity Read ↗

Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?Semantic proximity Read ↗

Glucose Restriction Combined with Autophagy Inhibition and Chemotherapy in HCT 116 Spheroids Decreases Cell Clonogenicity and Viability Regulated by Tumor Suppressor GenesSemantic proximity Read ↗

Developing the Theory of Toxic Chemotherapeutic Nutrition for Cancer Cells and Targeting Tumors via Glucose Mutation: Medical Guidance and Integrated Therapeutic ApproachSemantic proximity Read ↗

Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100Semantic proximity Read ↗

A New Strategy to Fight Metallodrug Resistance: Mitochondria‐Relevant Treatment through Mitophagy to Inhibit Metabolic Adaptations of Cancer CellsSemantic proximity Read ↗

Developing the theory of Toxic Chemotherapeutic Nutrition for Cancer Cells: Glucosodiene Polymer Structure, Safety, Efficacy, and Human Outcomes in Targeting Tumors via Glucose Mutation.Semantic proximity Read ↗

Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg EffectSemantic proximity Read ↗

The role and therapeutic potential of glucose metabolism in multidrug resistance of cancerSemantic proximity Read ↗

Three-dimensional multicellular spheroid-induced 5-fluorouracil drug resistance provokes global alterations of HeLa carcinoma cells: a multi-omics analysisSemantic proximity Read ↗

Metabolic drug survey highlights cancer cell dependencies and vulnerabilities.Semantic proximity Read ↗

Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.